Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 79   

Articles published

ARNA 4.49 +0.05 (1.13%)
price chart
Arena Pharmaceuticals to Present at the Annual Needham Healthcare Conference
SAN DIEGO, April 9, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the 14th Annual Needham Healthcare Conference on Wednesday, ...
Stock Analysis on Arena Pharmaceuticals Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc. (ARNA) reported last quarter earnings figures on March 02nd. The company announced actual earnings per share of $-0.15 against the consensus Street estimate of $-0.12.
Closing Bell Reports: Arena Pharmaceuticals, Inc. (ARNA), Rio Tinto plc (RIO ...  WallStreet Scope
Notable Stocks - Arena Pharmaceuticals, (ARNA), Owens Corning (OC), Plug ...  Techsonian (press release)
Arena Investors Need To Pay Attention To Competition
If you are invested in Arena Pharmaceuticals (NASDAQ:ARNA), some news delivered today by competitor Orexigen (NASDAQ:OREX) is something that you need to consider.
Orexigen Therapeutics Embarrasses Arena and VIVUS Again (VVUS, OREX ...  SmallCap Network
Arena - Belviq Television Advertising Disappointing In March
March has come to a close, and once again it is time to look at the advertising campaign for Arena pharmaceuticals' (NASDAQ:ARNA) anti-obesity medication Belviq. With the beginning of 2015, Arena's marketing partner Eisai promised more advertising.
Arena Pharmaceuticals, Inc. Discloses Insider Transaction
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), The Director, of ARENA PHARMACEUTICALS INC, Woods Randall E had unloaded 76,268 shares at $4.49 per share in a transaction on March 30, 2015.
Arena Pharmaceuticals Given Average Rating of "Hold" by Brokerages ...
Arena Pharmaceuticals (NASDAQ:ARNA) last released its earnings data on Monday, March 2nd. The company reported ($0.15) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.12) by $0.03.
Pre-Market Strong Movers � Eldorado Gold Corporation, (NYSE:EGO), Arena ...
Arena Pharmaceuticals, and Eisai Inc. declared the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of lorcaserin, as contrast ...
Stock's Buzzers - Arena Pharmaceuticals (ARNA), News (NWSA), Abbott ...  Techsonian (press release)
Update: Short Interest of Arena Pharmaceuticals, Inc. Increases by 0.6%
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has witnessed a rise of 0.6% or 191,796 shares in its short figure. The short interest augmentation took it from 34,251,689 on March 13,2015 to 34,443,485 on March 31,2015 .
Brokerage Firm Price Target on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock has received a short term price target of $ 7.3 from 5 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $2.49.
Traders Stocks Alert: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Alexion ...
Eisai Inc. and Arena Pharmaceuticals, Inc. (ARNA) on Apr. 10 announced the completion of two Phase 1 registrational clinical trials that Eisai and Arena believe demonstrate bioequivalence of an investigational once-daily extended release formulation of ...
Healthcare Sector Movers: Akorn, Inc. (AKRX), Alexion Pharmaceuticals, Inc ...  WallStreet Scope